Menu
06/12/2004
Experts complete review on safety of antidepressants
The Medicines and Healthcare products Regulatory Agency (MHRA) issued new advice to patients and doctors about the group of antidepressants known as SSRI's, today.
The updated advice follows the biggest and most thorough review of Selective Serotonin Reuptake Inhibitors (SSRI) antidepressants, by an independent group of medical experts. The review, which examined hundreds of clinical trials, was set up to look at the safety of SSRIs, with a particular emphasis on possible suicidal behaviour and withdrawal reactions.
The review findings are: There should be strengthened warnings about the risk of experiencing withdrawal reactions at the end of a course of treatment with SSRIs; In the majority of cases, the lowest recommended dose of SSRI's should be prescribed; From the available clinical trial data, both published and unpublished, a modest increase in the risk of suicidal thoughts and self-harm for SSRIs compared with placebo cannot be ruled our; There is good evidence from large population studies that there is no clear increase in the risk of suicide from SSRIs compared to other antidepressants; Careful and frequent patient monitoring by healthcare professionals and where appropriate other carers, is important in the early stages of treatment; And young adults should be closely monitored, as a precautionary measure, when being treated with SSRI's.
The CSM also recommended that in further research on the safety and efficacy of SSRIs, young adults should be assessed separately.
The Committee on Safety of Medicines also recommended that treatment with venlafaxine (Efexor) should only be started by specialists and there should be arrangements in place for ongoing supervision of the patient. Patients with heart disease should not be given venlafaxine at all.
The new advice for stronger and clearer warnings in certain areas will result in changes to patient information leaflets with the medicines.
Professor Kent Woods, Chief Executive of the MHRA, said: "The CSM Expert Group has now delivered comprehensive advice on the use of these drugs in children, young people and adults following a thorough review of all the evidence available. This gives parents, patients and those who treat these devastating and debilitating illnesses the information they need to make informed decisions about treatment.
"SSRIs are an important group of medicines, which help patients who suffer depressive illness. The benefits of SSRIs in adults are still considered to outweigh the risk of adverse drug reactions. Patients currently taking venlafaxine should not stop taking their medicine but should consult their doctor for advice on treatment as should patients taking other SSRIs who are experiencing any side effects or are concerned about their treatment".
Professor Louis Appleby, National Director for Mental Health, said: "The CSM has delivered one of the most comprehensive reviews of a class of medicines ever to be completed and it has been painstaking work, examining evidence from literally hundreds of clinical trials. What's important now is that their advice is put into practice. Publication of the NICE guidelines gives us the tools to do the job so that patients and prescribers can together make the best informed decisions."
(GB/MB)
The updated advice follows the biggest and most thorough review of Selective Serotonin Reuptake Inhibitors (SSRI) antidepressants, by an independent group of medical experts. The review, which examined hundreds of clinical trials, was set up to look at the safety of SSRIs, with a particular emphasis on possible suicidal behaviour and withdrawal reactions.
The review findings are: There should be strengthened warnings about the risk of experiencing withdrawal reactions at the end of a course of treatment with SSRIs; In the majority of cases, the lowest recommended dose of SSRI's should be prescribed; From the available clinical trial data, both published and unpublished, a modest increase in the risk of suicidal thoughts and self-harm for SSRIs compared with placebo cannot be ruled our; There is good evidence from large population studies that there is no clear increase in the risk of suicide from SSRIs compared to other antidepressants; Careful and frequent patient monitoring by healthcare professionals and where appropriate other carers, is important in the early stages of treatment; And young adults should be closely monitored, as a precautionary measure, when being treated with SSRI's.
The CSM also recommended that in further research on the safety and efficacy of SSRIs, young adults should be assessed separately.
The Committee on Safety of Medicines also recommended that treatment with venlafaxine (Efexor) should only be started by specialists and there should be arrangements in place for ongoing supervision of the patient. Patients with heart disease should not be given venlafaxine at all.
The new advice for stronger and clearer warnings in certain areas will result in changes to patient information leaflets with the medicines.
Professor Kent Woods, Chief Executive of the MHRA, said: "The CSM Expert Group has now delivered comprehensive advice on the use of these drugs in children, young people and adults following a thorough review of all the evidence available. This gives parents, patients and those who treat these devastating and debilitating illnesses the information they need to make informed decisions about treatment.
"SSRIs are an important group of medicines, which help patients who suffer depressive illness. The benefits of SSRIs in adults are still considered to outweigh the risk of adverse drug reactions. Patients currently taking venlafaxine should not stop taking their medicine but should consult their doctor for advice on treatment as should patients taking other SSRIs who are experiencing any side effects or are concerned about their treatment".
Professor Louis Appleby, National Director for Mental Health, said: "The CSM has delivered one of the most comprehensive reviews of a class of medicines ever to be completed and it has been painstaking work, examining evidence from literally hundreds of clinical trials. What's important now is that their advice is put into practice. Publication of the NICE guidelines gives us the tools to do the job so that patients and prescribers can together make the best informed decisions."
(GB/MB)
Related UK National News Stories
Click here for the latest headlines.
22 September 2008
Scottish Government Pledges Cap On Surgery Waiting Times
Scottish patients may soon have a legal guarantee that they will wait no longer than 12 weeks for surgery. The Scottish Government's Patient Rights Bill proposes a strict limit on how long they have to wait from their surgical referral to receiving their operation.
Scottish Government Pledges Cap On Surgery Waiting Times
Scottish patients may soon have a legal guarantee that they will wait no longer than 12 weeks for surgery. The Scottish Government's Patient Rights Bill proposes a strict limit on how long they have to wait from their surgical referral to receiving their operation.
17 April 2009
Older Stroke Patients Get Poorer Treatment, Says BMJ
Older people are less likely to receive drug treatment after a stroke compared to younger people, despite the fact that treatment is equally effective. A study published on bmj.
Older Stroke Patients Get Poorer Treatment, Says BMJ
Older people are less likely to receive drug treatment after a stroke compared to younger people, despite the fact that treatment is equally effective. A study published on bmj.
06 July 2005
Patients prefer better care to faster treatment, report claims
Patients would prefer to wait for better hospital treatment, rather than go to a hospital with shorter waiting lists. A study, conducted by RAND Europe, the King’s Fund and City University, found that patients were more likely to choose to be treated at a hospital with a good reputation rather than one that has shorter waiting times.
Patients prefer better care to faster treatment, report claims
Patients would prefer to wait for better hospital treatment, rather than go to a hospital with shorter waiting lists. A study, conducted by RAND Europe, the King’s Fund and City University, found that patients were more likely to choose to be treated at a hospital with a good reputation rather than one that has shorter waiting times.
04 August 2004
NHS patients not consulted enough during treatment, says survey
Many NHS patients are not involved enough in decisions about their care and so cannot give meaningful consent to treatment, according to the Healthcare Commission. Over 300,000 patients were asked about their experiences in 568 English NHS trusts for five commission the surveys published today.
NHS patients not consulted enough during treatment, says survey
Many NHS patients are not involved enough in decisions about their care and so cannot give meaningful consent to treatment, according to the Healthcare Commission. Over 300,000 patients were asked about their experiences in 568 English NHS trusts for five commission the surveys published today.
14 August 2014
30 Women Recalled For Breast Screening Over Doctor Concerns
Up to 30 women are to be recalled for breast cancer screenings after five patients treated by the same doctor developed the disease. Oxford University Hospitals NHS Trust has identified the group of 30 women from a total of 626 that were seen between 2011 and 2014. It is understood that the women need "urgent appointments" for reassessment.
30 Women Recalled For Breast Screening Over Doctor Concerns
Up to 30 women are to be recalled for breast cancer screenings after five patients treated by the same doctor developed the disease. Oxford University Hospitals NHS Trust has identified the group of 30 women from a total of 626 that were seen between 2011 and 2014. It is understood that the women need "urgent appointments" for reassessment.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
